The Technology Is Ready. Are APAC's Regulators? Continuous Manufacturing Faces a Standoff in Asia-Pacific

Continuous and intensified bioprocessing, now backed by a dedicated international guideline in ICH Q13, promises smaller plants, faster campaigns and lower cost per gram. Yet across Asia-Pacific, the promise carries an uncomfortable dependency: manufacturers will not commit capital until the approval pathway is predictable, and regulators are reluctant to publish detailed expectations until they see real dossiers moving through their systems. Each side is waiting for the other to move first.

The hardware works. The software works. What stalls the capital request that would turn a pilot line into a commercial one is rarely an engineering question. It is a regulatory one: will the national authority accept a batch that was never a batch in the old sense, released not by a certificate of analysis at the end but by a continuous demonstration of control throughout?

The value case: why continuous is worth the fight

Strip continuous manufacturing back to its economics and the appeal is straightforward. A traditional batch process makes medicine in discrete steps, with material sitting in hold tanks and quarantine between each one while samples are pulled and tested. A continuous process connects two or more of those steps so that material flows through without the stop-start. The result is less idle inventory, smaller equipment running for longer, and a dramatically smaller building to house it all.

The headline numbers are striking. Analyses of continuously manufactured products point to production-time reductions on the order of ninety percent against equivalent batch routes, and by 2025 more than fifteen products made using continuous processes had cleared the US FDA (搜索)搜索该词条. The best-known small-molecule examples, Vertex查看公司主页's cystic fibrosis therapies and Johnson & Johnson查看公司主页's Prezista among them, showed that hybrid and fully continuous lines could win approval and hold up commercially.

For biologics the logic runs deeper still. Perfusion upstream, paired with connected downstream capture and polishing, lets a small bioreactor match the output of a far larger fed-batch tank by running continuously and harvesting constantly. Single-use assemblies, now present in an estimated forty to fifty percent of new biologic production lines, slot naturally into that model because they remove cleaning and changeover time between campaigns. The combined effect is a facility that is smaller, cheaper to build, quicker to bring online and easier to reconfigure for the next product.

Market forecasts reflect this pull: continuous bioprocessing is widely projected to grow faster in Asia Pacific than in any other region. The region holds some of the world's fastest-growing biomanufacturing capacity, much of it still on the drawing board rather than locked into legacy batch plants. That makes the prize unusually large: a chance to leapfrog straight to continuous, intensified facilities without the cost of retrofitting.

The control-strategy shift: proving quality a different way

The reason continuous manufacturing is a regulatory question and not merely an engineering one comes down to how quality is demonstrated. In a batch world, control is largely retrospective. Continuous manufacturing cannot work that way, because there is no discrete batch sitting in quarantine waiting for a certificate. Quality has to be assured as the material flows.

That inverts the logic of validation. Instead of proving quality after the fact, a continuous line must demonstrate a continuous state of control, monitored in real time and backed by the ability to detect and divert any material that drifts out of specification. The enabling toolkit is process analytical technology, or PAT: spectroscopic probes, in-line sensors and soft-sensor models that read critical quality attributes as the process runs rather than in a lab hours later. Real-time release testing, where the decision to release rests on process and in-line data rather than end-product testing alone, is the destination that PAT makes possible.

ICH Q13, adopted by the International Council for Harmonisation at Step 4 in November 2022, is the document that codifies this thinking for continuous manufacturing specifically. It is deliberately technology-neutral, describing concepts, scientific approaches and regulatory considerations rather than prescribing hardware, and it leans heavily on the quality-by-design and lifecycle principles laid down across ICH Q8 through Q12. Its Annex III addresses therapeutic proteins directly, acknowledging the added complexity of living systems: variable cell performance, intricate downstream purification, and the need to hold product quality steady across a long continuous run.

"The hardest shift is not the equipment, it is the mindset. Assessors trained on batch records have to get comfortable releasing on a state of control they cannot read off a single number."

For regulators, that is precisely the challenge. Assessing a continuous dossier requires reviewers fluent in PAT, chemometric models, control engineering and diversion logic, not just analytical chemistry. It requires inspectors who can walk a continuous line and interrogate its control system rather than its batch paperwork. Building that capability takes time and specialist hiring, and no agency wants to invest heavily in it speculatively.

The regulatory state: reading the ICH Q13 map across APAC

Because Q13 is an ICH guideline, its reach across Asia Pacific tracks closely with each authority's relationship to ICH. That relationship, more than any single policy, is the best first indicator of how ready a given regulator is to receive a continuous manufacturing dossier.

Japan's PMDA sits at the front of the pack. As a founding regulatory member of ICH, it implemented Q13 in step with the guideline's international timetable, publishing the adopted text in 2023, and it had already developed its own thinking on continuous manufacturing for both small molecules and biologics ahead of that. Of the APAC authorities, PMDA is the one a manufacturer can approach today with the least uncertainty.

China's NMPA has moved on the structural barriers rather than issuing a signature rulebook. An ICH member since 2017, its October 2024 pilot allowing non-end-to-end, or segmented, manufacturing of biologics matters because it loosens a longstanding requirement that drug substance and drug product be made at a single site, a rule that sat awkwardly with distributed and continuous models. The agency also offers expedited review for products using innovative manufacturing technology that show clear patient benefit.

India's CDSCO (搜索)搜索该词条 is the region's paradox. As the world's largest supplier of generic medicines, India has more to gain from continuous manufacturing's cost advantage than almost anyone, and yet its regulator has moved cautiously. CDSCO participates in ICH as an observer and has engaged with advanced manufacturing through joint workshops alongside the US FDA (搜索)搜索该词条, PMDA and TGA. Its recent draft legislation on manufacturing-change approvals shows an agency modernising its post-approval framework.

Singapore's HSA plays a different game. It regulates a small domestic market but carries outsized credibility, having been recognised by the WHO at the highest tier of regulatory maturity. HSA is unlikely to author a pioneering continuous manufacturing framework of its own, but its sophisticated, reliance-based approach means it can accept innovation validated by trusted reference regulators quickly.

Australia's TGA rounds out the group. As an ICH member it adopts ICH guidance including Q13, and it leans on comparable-overseas-regulator pathways that let it rely on assessments from peer agencies. Its reliance mechanisms make it a low-friction destination once a dossier has cleared a major market.

The standoff, and the first movers who break it

If the problem is that each side waits for the other, the solution is a mechanism that lets one side move without betting the whole business on the other. Three are already visible in APAC.

The first is the regulator-run pilot. Rather than publishing an exhaustive rulebook up front, an agency invites a small number of real continuous manufacturing programmes into a structured, closely supervised channel and learns by doing. NMPA's segmented-manufacturing pilot is one version of this. Internationally, the US FDA (搜索)搜索该词条's Advanced Manufacturing Technologies designation, finalised in early 2025 and first awarded that April, offers a template APAC agencies can borrow: a formal designation that grants innovative manufacturing approaches earlier and more intensive engagement with reviewers.

The second is the contract manufacturer. A CDMO that builds continuous, single-use, intensified capacity spreads that capital across many clients, which changes the investment maths entirely. CDMOs in China and Korea are already establishing continuous and turnkey single-use capabilities. An individual drug owner may hesitate to build a continuous plant for one product; a CDMO can build the platform once and offer it to dozens, becoming the wedge that gets the first APAC continuous dossiers written.

The third is the reference dossier. Every continuous manufacturing filing that clears a credible regulator lowers the barrier for the next, both by teaching the agency and by giving reliance-based authorities something to rely on. Once a continuous product is approved by a reference regulator, HSA and TGA can move quickly, and even more conservative agencies gain a worked example to benchmark against.

"The technology stopped being the bottleneck a while ago. The real question is which regulator will let it into a filing."

Leapfrog, or stuck?

The case for leapfrogging is real. Much of APAC's biomanufacturing capacity is still being planned rather than defended, which means there is less legacy batch infrastructure to write off and more appetite for building right the first time. The region's reliance frameworks let smaller agencies accept innovation proven elsewhere without having to originate it. And the commercial pressure—to serve vast domestic populations, to compete in export markets and to withstand supply shocks—points hard toward the smaller, cheaper, more flexible facilities that continuous manufacturing delivers.

The case for staying stuck is equally real, and it is mostly about coordination rather than capability. If manufacturers keep waiting for fully detailed pathways, and regulators keep waiting for dossiers before they build those pathways, the standoff simply persists, and the capacity gets built as conventional batch because that is the known quantity. Nothing about the technology forces a resolution. Only decisions do.

What the evidence suggests is that the break will not come from a grand regional policy. It will come from specific pairings: PMDA with a Japanese continuous line already in operation, NMPA with a segmented-manufacturing pilot participant, a Singapore or Korean CDMO with a flagship client willing to file first. Each of those is a small crack in the standoff. Enough of them, and the chicken-and-egg stops being a question at all. The technology is ready. Whether APAC's regulators and manufacturers stop waiting for each other is the only variable left.